CTLA4 and nonpapillary renal cell carcinoma: Three studies have reported ccRCC single-cell profiles across disease stages (Braun et al., 2021; Borcherding et al., 2021) or in the context of ipilimumab (anti-CTLA4) plus nivolumab (Krishna et al., 2021).